^
Association details:
| Biomarker: | KRAS G12C + PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic nonsquamous NSCLC with PD-L1 low
Published date:
03/23/2022
Excerpt:
In the context of chemo-IO combo, our study aims to compare platinum-pemetrexed-pembrolizumab (PPP) combo to platinum-doublet alone in pts with low PD-L1 (<50%)…KRAS G12C was associated with better PFS (HR 0.33, 95%CI 0.11-1.04).
Secondary therapy:
pemetrexed
